Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

struminbanjobio Aug. 4 at 12:03 AM

$PRQR smells like something big is brewing

0 · Reply

ehpats Aug. 3 at 10:22 PM

$PRQR let’s see if the director with the M&A background follows suit. He has so far.

0 · Reply

CEOBuysDisclosures Aug. 3 at 10:05 PM

$PRQR CEO purchased 200,000 shares at $1.77 for a total of $353,960. de Boer Daniel Anton now owns 500,000 shares. https://ceo-buys.com

0 · Reply

ehpats Aug. 3 at 8:31 PM

$PRQR I remain stumped as to why these significant insiders purchases don’t move the market. Generally these things are seen as a positive sign but apparently not with Prqr.

1 · Reply

ehpats Aug. 3 at 8:28 PM

$PRQR CEO with another 200k purchase on the open market. Now owns 500k shares. 👍

1 · Reply

Ironboot Jul. 31 at 2:52 PM

$PRQR I read the Van Herk vs ProQR petition so that you dont have to. Van Herk is demanding that the Dutch enterprise chamber court initiates an investigation into the corporate governance practices at ProQR and in the meantime appoints an independent board member. Main allegations are about various breaches of corporate governance rules and practices. This was already raised by Van Herk in 2025. Some important takeaways for us shareholders from this case 1. CEO received a significant bonus in 2025. It is not clear what KPIs were triggered. Van Herk thinks its intransparent and unfair. Can this bonus be from progress with confidential Lilly programs? 2. CEO and the board agreed that CEO will receive a huge bonus in case of takeover - 2 annual salaries + immediate vesting of all options. Are they preparing to sell the whole shop to Lilly and pushing the CEO to wrap this up? https://www.sec.gov/Archives/edgar/data/1612940/000110465926088126/tm2621582d1_ex99-2.htm

1 · Reply

HeartOfTheCrow Jul. 30 at 9:29 AM

$PRQR Van Herk (10.9% ownership) formally petitioning for the appointment of a new, independent non-executive director to the company’s board. Filed July 27th.

1 · Reply

johnnygogogo Jul. 30 at 3:43 AM

$PRQR Aberdeen added 5,615,542 shares. New total 8,932,507. Probably nothing.

1 · Reply

AZOZ Jul. 28 at 2:01 PM

$PRQR Insider love it right now Stay tuned folks!

1 · Reply

Filvul Jul. 28 at 11:39 AM

$PRQR this is so undervalued....

1 · Reply

ProQR Therapeutics registers to sell 3.03M ordinary shares for holders

Jul 6, 2026, 8:00 AM EDT - 4 weeks ago

ProQR Therapeutics Registration statement: Registration filing

2026-06-26T11:35:19.000Z - 5 weeks ago

ProQR Therapeutics price target lowered to $10 from $14 at Raymond James

2026-06-26T08:40:08.000Z - 5 weeks ago

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

2026-06-26T00:55:07.000Z - 5 weeks ago

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Jun 25, 2026, 7:00 AM EDT - 5 weeks ago

ProQR Therapeutics Slides: Conference presentation

2026-06-25T10:40:22.000Z - 5 weeks ago

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

LLY

2026-06-25T10:35:33.000Z - 5 weeks ago

ProQR Therapeutics announces positive Phase 1 data for AX-0810

Jun 25, 2026, 6:35 AM EDT - 5 weeks ago

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Jun 25, 2026, 6:25 AM EDT - 5 weeks ago

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

May 12, 2026, 7:00 AM EDT - 2 months ago

ProQR Announces First Quarter 2026 Operating and Financial Results

May 12, 2026, 7:00 AM EDT - 2 months ago

ProQR Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

May 4, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

2026-04-08T20:45:41.000Z - 4 months ago

ProQR Therapeutics management to meet with Cantor Fitzgerald

2026-04-08T20:40:37.000Z - 4 months ago

ProQR Therapeutics management to meet with Oppenheimer

Apr 8, 2026, 4:00 PM EDT - 4 months ago

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Transcript: Status update

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Press release: Status update

Apr 8, 2026, 10:00 AM EDT - 4 months ago

ProQR Therapeutics Slides: Status update

Apr 8, 2026, 8:00 AM EDT - 4 months ago

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

2026-03-12T11:46:03.000Z - 5 months ago

ProQR Therapeutics assumed with an Outperform at Oppenheimer

2026-03-12T11:10:29.000Z - 5 months ago

ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

ProQR Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 3:25 PM EDT - 5 months ago

ProQR Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 3, 2026, 4:30 PM EST - 5 months ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

2026-02-19T15:50:54.000Z - 5 months ago

ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald

2026-02-09T13:05:14.000Z - 6 months ago

ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart

Feb 9, 2026, 8:00 AM EST - 6 months ago

ProQR Announces Planned Changes to Board Composition

2026-01-08T13:15:17.000Z - 7 months ago

ProQR announces initial safety, PK data from Phase 1 trial of AX-0810

LLY

Jan 8, 2026, 8:00 AM EST - 7 months ago

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 4, 2025, 8:20 AM EST - 8 months ago

ProQR Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 8:00 AM EST - 8 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 9:30 AM EST - 9 months ago

ProQR Therapeutics Earnings release: Q3 2025

2025-11-06T12:21:19.000Z - 9 months ago

ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year

Nov 6, 2025, 7:00 AM EST - 9 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Transcript: Study Update

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Press release: Study Update

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Slides: Study Update

Oct 21, 2025, 1:00 PM EDT - 10 months ago

ProQR Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

2025-10-20T12:05:08.000Z - 10 months ago

ProQR Therapeutics receives CTA authorization for AX-0810

Oct 20, 2025, 8:00 AM EDT - 10 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

2025-10-16T16:15:25.000Z - 10 months ago

ProQR Therapeutics management to meet with Citizens JMP

Oct 13, 2025, 8:30 AM EDT - 10 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 9:30 AM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q2 2025

2025-08-07T11:32:48.000Z - 1 year ago

ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year

2025-08-07T11:32:17.000Z - 1 year ago

ProQR Therapeutics sees cash runway into mid-2027

Aug 7, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

2025-07-11T18:15:22.000Z - 1 year ago

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Jun 26, 2025, 4:30 PM EDT - 1 year ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 11:30 AM EDT - 1 year ago

ProQR Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q1 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 1 year ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Annual report: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Press release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

ProQR Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 11, 2024, 10:00 AM EST - 1 year ago

ProQR Therapeutics Transcript: AGM 2024

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Nov 7, 2024, 9:30 AM EST - 1 year ago

ProQR Therapeutics Earnings release: Q3 2024

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Registration statement: Registration Filing

Sep 17, 2024, 9:10 AM EDT - 2 years ago

ProQR Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 2 years ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Aug 8, 2024, 7:21 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q2 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Transcript: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Press release: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Slides: Status Update

May 9, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 2:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 2 years ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 2 years ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Annual report: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q4 2023

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 5:00 AM EST - 2 years ago

ProQR Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q2 2023

Aug 1, 2023, 7:00 AM EDT - 3 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 6, 2023, 7:00 AM EDT - 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 16, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

struminbanjobio Aug. 4 at 12:03 AM

$PRQR smells like something big is brewing

0 · Reply

ehpats Aug. 3 at 10:22 PM

$PRQR let’s see if the director with the M&A background follows suit. He has so far.

0 · Reply

CEOBuysDisclosures Aug. 3 at 10:05 PM

$PRQR CEO purchased 200,000 shares at $1.77 for a total of $353,960. de Boer Daniel Anton now owns 500,000 shares. https://ceo-buys.com

0 · Reply

ehpats Aug. 3 at 8:31 PM

$PRQR I remain stumped as to why these significant insiders purchases don’t move the market. Generally these things are seen as a positive sign but apparently not with Prqr.

1 · Reply

ehpats Aug. 3 at 8:28 PM

$PRQR CEO with another 200k purchase on the open market. Now owns 500k shares. 👍

1 · Reply

Ironboot Jul. 31 at 2:52 PM

1 · Reply

HeartOfTheCrow Jul. 30 at 9:29 AM

$PRQR Van Herk (10.9% ownership) formally petitioning for the appointment of a new, independent non-executive director to the company’s board. Filed July 27th.

1 · Reply

johnnygogogo Jul. 30 at 3:43 AM

$PRQR Aberdeen added 5,615,542 shares. New total 8,932,507. Probably nothing.

1 · Reply

AZOZ Jul. 28 at 2:01 PM

$PRQR Insider love it right now Stay tuned folks!

1 · Reply

Filvul Jul. 28 at 11:39 AM

$PRQR this is so undervalued....

1 · Reply

JeffersonSovereign Jul. 28 at 4:39 AM

$PRQR ehm lilly isnt random small player

0 · Reply

JeffersonSovereign Jul. 27 at 7:43 PM

$PRQR

0 · Reply

JeffersonSovereign Jul. 27 at 6:41 PM

$PRQR

2 · Reply

johnnygogogo Jul. 24 at 6:14 PM

$PRQR right now you can buy at the same price as the CEO and Director recently purchases, 150k shares at $1.72 and $1.74 but instead some of you will complain about the price not moving higher or not investing in AI slop instead

3 · Reply

Quantumup Jul. 24 at 2:13 PM

Stifel reiterated $MIRM Buy-$136 and saud -- Ipsen announced that their ph3 biliary atresia study failed which is unsurprising given the design (an outcomes study-a really challenging clinical setting). $IPSEY $PRQR GSK GNFTY GILD VIR Here's what Stifel went on to say: https://x.com/Quantumup1/status/2080657263291703391?s=20

0 · Reply

FutureInvesting777 Jul. 23 at 9:14 PM

$PRQR he may have already sold for at least quick $50K profit in few days :) :) :)

1 · Reply

ehpats Jul. 23 at 4:28 PM

$PRQR I would have thought the insider purchases would be viewed as extremely bullish and caused the PPS to run a little. Maybe we will see a delayed reaction. This needs to be $3+ 🤷

1 · Reply

JCLuckman Jul. 22 at 10:23 PM

$PRQR I will remember these days to add.....

0 · Reply

struminbanjobio Jul. 22 at 1:23 PM

$PRQR road to $3

2 · Reply

vu_jade Jul. 22 at 1:18 PM

$PRQR Insider buying, Lilly? Insiders buy for Only 1 reason …..

1 · Reply

Stockswingalert Jul. 22 at 12:14 AM

$PRQR after hours scan trying to break the 200ma 👀👀👀 Off the 150k share buy Fits the $XBI bio theme cc $LLY

2 · Reply

ehpats Jul. 21 at 9:01 PM

$PRQR volume strong. Maybe more form 4’s coming tomorrow or Thursday???

0 · Reply

Market Cap	181.22M
Revenue (ttm)	18.00M
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-265.17%
Debt to Equity Ratio	0.13

Volume	550,700
Avg Vol	1,067,048
Day's Range	N/A - N/A
Shares Out	105.36M
Stochastic %K	21%
Beta	0.04
Analysts	Strong Sell
Price Target	$8.25